We exploit the advantages of fragment screening to generate highly efficient lead candidates.
We combine high-throughput crystallography with biophysical methods to identify initial binders from a fragment library hand-selected by medicinal chemists. Subsequently, we apply fragment growing or linking approaches to structure determination to improve potency and selectivity. Our continuous access to high-brilliance synchrotron sources along with automated data collection allows fast and reliable retrieval of crystallographic data. Our inhouse established data analysis pipeline enables quick identification of datasets with high likelihood of fragment binding.
Please contact us for more information on our Fragment library and our Fragment2Lead Platform. One of our recent success stories can be found here: